Eventide Gilead Fund Completes First 10yrs Top 1% in Mid-Cap Growth Funds
Boston, MA – The Eventide Gilead Fund (NASDAQ: ETILX) celebrated its 10-year anniversary on July 8, 2018, completing its first 10 years ranked in the top 1% of the Morningstar Mid-Cap Growth category for total return out of 515 funds. The Eventide Gilead Fund ranked in the top 3% for the five-year period out of 573 funds, top 45% for the three-year period out of 596 funds, and top 7% for the one-year period out of 626 funds. The Fund’s prospectus requires a minimum investment of $100,000 for ETILX.*
The Eventide Funds are guided by an approach described as “investing that makes the world rejoice.” Eventide CIO and Gilead Fund lead portfolio manager Finny Kuruvilla, MD PhD explained: “Business has the ability to create wealth, yet we believe the true purpose of business is something far greater — to provide for the material needs of the world. By investing in companies that fulfill this purpose, our investors have helped to make the world rejoice. We are delighted to have been able to provide superior performance as well.”
Eventide CEO Robin John offered this comment: “We are so proud of what our investors are a part of. Our investors have been able to see their investment dollars helping to advance the global common good. Investing in this way gives our investors a real sense of personal wholeness and purpose. With the good performance result as well, we couldn’t be happier.”
When asked how this philosophy plays out in practice, Dr. Kuruvilla said, “Part of our approach includes investing in what we call ‘themes of human flourishing.’ These are themes we believe are attractive for growth potential and for meeting human needs, such as health and safety, cybersecurity, renewable power production, and automated driving. From within these themes we then look for high quality companies exhibiting sustainable competitive advantages, great management teams, rich company culture, and a focus on creating value for stakeholders. The goal is to invest in companies where business strategy and business ethics combine to produce performance and a better world.”
The Eventide Gilead Fund seeks to provide long-term capital appreciation. The Eventide Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser managing more than $2.8 billion in net assets.
© 2018 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Morningstar is an independent provider of financial information. Morningstar rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. Rankings are only one form of performance measurement.
Morningstar percentile ranking is an investment’s total return percentile rank against others in its Morningstar Category, ranging from 1 (best) to 100 (worst). The ranking does not account for sales loads, where applicable.
Morningstar’s ranking of ETILX is based on the Fund’s performance from its inception date of February 2, 2010 to July 8, 2018. For the remaining period prior to the inception of ETILX, Morningstar applies the performance of ETGLX.
*Other Gilead Fund share classes offer lower investment minimums. The rankings for other share classes are lower based on fees. Other share classes: NASDAQ: ETGLX, NASDAQ: ETAGX, NASDAQ: ETCGX.
Registration as an investment adviser does not imply a certain level of skill or training. The above expresses the views of Eventide Asset Management, LLC, and there is no guarantee that such views are accurate. Eventide’s approach may not produce the desired results.
Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Funds’ ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Eventide Gilead Fund can invest in smaller-sized companies that may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Investors should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the industrial sector also carry various risks including, but not limited to, risk related to debt loads and intense competition.
An investor should consider a fund’s investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.
Director of Marketing
877-771-EVEN (3836), x56
Download the print version of this article.